Pro-Dex (PDEX) Investor presentation summary

Investment highlights

• High-growth contract manufacturer with a focus on finished medical devices and strong long-term partnerships with leading orthopedic OEMs.

• Proprietary IP portfolio and stable core cash flow support sustainable growth.

• Expanding into disposable and single-use markets, with established credibility among major manufacturing partners.

• Active opportunity pipeline through surgeon and university collaborations.

• Provider of engineering and QA/RA services, with long-term manufacturing contracts.

Financial performance and key figures

• Revenue grew from $22M in 2018 to $75M in 2025, with a CAGR of ~17%.

• Share price reached $66.93 as of June 1, 2026, with TTM EPS at $3.59.

• Book value stands at $45.2M, market cap at $157M, and $10M in cash available.

• 208 total employees and approximately 3.2M shares outstanding.

• PE ratio is 13.7x as of March 31, 2026.

Capabilities and facilities

• Full-scale precision manufacturing infrastructure, including engineering, regulatory, manufacturing, and quality systems.

• Facilities in Irvine and Tustin, CA, with specialized areas for machining, assembly, cleanroom operations, and R&D.

• Capabilities include 510(k) submissions, sterilization, safety testing, and biocompatibility assessments.

• Quality systems feature master validation plans, control plans, and final inspection protocols.